Emcure Pharmaceuticals: Key Financial Highlights and Recent News
Revenue and Profit
Emcure Pharmaceuticals Limited has reported a significant 11.33% increase in revenue for the financial year ending March. However, its profit after tax (PAT) has declined by 61% during the same period.
Anchor Book Raise
Emcure Pharma has successfully raised Rs 5,826 crore through an anchor book allocation of 5,779,850 shares to anchor investors at Rs 1,008 per share.
Financial Summary
Here is a summary of key financial information for Emcure Pharmaceuticals Limited for the financial year ending March 31:
- Revenue: Increased by 11.33%
- PAT: Decreased by 61%
Lawsuit
Emcure Pharmaceuticals Limited is facing a lawsuit filed by HDT Bio Corp in the United States District Court Seattle Division. The details of the lawsuit are currently not available.
Sales Growth
Over the past five years, Emcure Pharmaceuticals has experienced a relatively slow sales growth of 7.14%.
Komentar